111 related articles for article (PubMed ID: 37648468)
1. Impact of sarcopenia on S1 adjuvant chemotherapy and prognosis in pancreatic cancer patients.
Takagi K; Inoue Y; Oba A; Ono Y; Sato T; Ito H; Saino Y; Saiura A; Takahashi Y
Biosci Trends; 2023 Sep; 17(4):310-317. PubMed ID: 37648468
[TBL] [Abstract][Full Text] [Related]
2. Postoperative Serum Albumin Level is a Marker of Incomplete Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma.
Matsumoto I; Tanaka M; Shirakawa S; Shinzeki M; Toyama H; Asari S; Goto T; Yamashita H; Ishida J; Ajiki T; Fukumoto T; Shimokawa M; Ku Y
Ann Surg Oncol; 2015 Jul; 22(7):2408-15. PubMed ID: 25487967
[TBL] [Abstract][Full Text] [Related]
3. The impact of changes in radiographic sarcopenia on overall survival in older adults undergoing different treatment pathways for pancreatic cancer.
Benjamin AJ; Buschmann MM; Zhang SQ; Wroblewski K; Kindler HL; Roggin KK; Dale W
J Geriatr Oncol; 2018 Jul; 9(4):367-372. PubMed ID: 29534880
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Adjuvant Chemotherapy Following Pancreaticoduodenectomy in Elderly Patients With Pancreatic Cancer.
Shin SH; Park Y; Hwang DW; Song KB; Lee JH; Kwon J; Yoo C; Alshammary S; Kim SC
Anticancer Res; 2019 Feb; 39(2):1005-1012. PubMed ID: 30711988
[TBL] [Abstract][Full Text] [Related]
5. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
6. Impact of adjuvant chemotherapy after pancreaticoduodenectomy for distal cholangiocarcinoma: a propensity score analysis from a French multicentric cohort.
Bergeat D; Turrini O; Courtin-Tanguy L; Truant S; Darnis B; Delpero JR; Mabrut JY; Regenet N; Sulpice L
Langenbecks Arch Surg; 2018 Sep; 403(6):701-709. PubMed ID: 30112638
[TBL] [Abstract][Full Text] [Related]
7. Sarcopenia as a prognostic factor in patients with recurrent pancreatic cancer: a retrospective study.
Sakamoto T; Yagyu T; Uchinaka E; Miyatani K; Hanaki T; Kihara K; Matsunaga T; Yamamoto M; Tokuyasu N; Honjo S; Fujiwara Y
World J Surg Oncol; 2020 Aug; 18(1):221. PubMed ID: 32828127
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of preoperative psoas muscle index as a measure of nutritional status in patients with esophageal cancer receiving neoadjuvant therapy.
Nakayama T; Furuya S; Kawaguchi Y; Shoda K; Akaike H; Hosomura N; Amemiya H; Kawaida H; Sudoh M; Kono H; Ichikawa D
Nutrition; 2021 Oct; 90():111232. PubMed ID: 33964490
[TBL] [Abstract][Full Text] [Related]
9. The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy.
Takeda T; Sasaki T; Suzumori C; Mie T; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Int J Clin Oncol; 2021 Jul; 26(7):1293-1303. PubMed ID: 33791917
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Outcomes After Pancreatectomy for Pancreatic Ductal Adenocarcinoma in Elderly Patients: Special Reference to Postoperative Adjuvant Chemotherapy.
Watanabe Y; Shinkawa T; Endo S; Abe Y; Nishihara K; Nakano T
World J Surg; 2018 Aug; 42(8):2617-2626. PubMed ID: 29383429
[TBL] [Abstract][Full Text] [Related]
11. Patterns of Adjuvant Chemotherapy Use and Association With Survival in Adults 80 Years and Older With Pancreatic Adenocarcinoma.
Mehtsun WT; McCleary NJ; Maduekwe UN; Wolpin BM; Schrag D; Wang J
JAMA Oncol; 2022 Jan; 8(1):88-95. PubMed ID: 34854874
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
Kim IH; Choi MH; Lee IS; Hong TH; Lee MA
BMC Cancer; 2021 Jan; 21(1):77. PubMed ID: 33461517
[TBL] [Abstract][Full Text] [Related]
13. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy in pancreatic cancer at different AJCC stages: a propensity score matching analysis.
Li XH; Zhou EL; Dong XY; Zhao CY; Han YX; Cui BK; Lin XJ
Eur J Med Res; 2023 Dec; 28(1):606. PubMed ID: 38115156
[TBL] [Abstract][Full Text] [Related]
15. The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensity.
Yabusaki N; Fujii T; Yamada S; Murotani K; Sugimoto H; Kanda M; Nakayama G; Koike M; Fujiwara M; Kodera Y
Medicine (Baltimore); 2016 Jul; 95(29):e4282. PubMed ID: 27442667
[TBL] [Abstract][Full Text] [Related]
16. Preoperative sarcopenia is associated with poor overall survival in pancreatic cancer patients following pancreaticoduodenectomy.
Peng YC; Wu CH; Tien YW; Lu TP; Wang YH; Chen BB
Eur Radiol; 2021 Apr; 31(4):2472-2481. PubMed ID: 32974690
[TBL] [Abstract][Full Text] [Related]
17. Correlation between the skeletal muscle index and surgical outcomes of pancreaticoduodenectomy.
Sui K; Okabayshi T; Iwata J; Morita S; Sumiyoshi T; Iiyama T; Shimada Y
Surg Today; 2018 May; 48(5):545-551. PubMed ID: 29285616
[TBL] [Abstract][Full Text] [Related]
18. Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma.
Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K
Cancer Chemother Pharmacol; 2021 Jul; 88(1):109-120. PubMed ID: 33825991
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
Oettle H; Post S; Neuhaus P; Gellert K; Langrehr J; Ridwelski K; Schramm H; Fahlke J; Zuelke C; Burkart C; Gutberlet K; Kettner E; Schmalenberg H; Weigang-Koehler K; Bechstein WO; Niedergethmann M; Schmidt-Wolf I; Roll L; Doerken B; Riess H
JAMA; 2007 Jan; 297(3):267-77. PubMed ID: 17227978
[TBL] [Abstract][Full Text] [Related]
20. The impact of sarcopenia and decrease in skeletal muscle mass in patients with advanced pancreatic cancer during FOLFIRINOX therapy.
Uemura S; Iwashita T; Ichikawa H; Iwasa Y; Mita N; Shiraki M; Shimizu M
Br J Nutr; 2021 May; 125(10):1140-1147. PubMed ID: 32883372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]